Press Releases on July 12, 2024 - EIN Presswire - Press Release Distribution Service

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Imvanex, Modified Vaccinia Ankara - Bavarian Nordic virus (smallpox), ...

P/0284/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for modified vaccinia Ankara - Bavarian Nordic virus (smallpox) (Imvanex), (EMEA-001161-PIP02-11-M03) Reference Number: EMA/288064/ …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Taltz, ixekizumab, decision type: PM: decision on the application for ...

P/0049/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMEA-001050-PIP02-18-M02) Reference Number: EMA/287810/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Imlygic, talimogene laherparepvec, decision type: PM: decision on the ...

P/0275/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMEA-001251-PIP01-11-M06) Reference Number: EMA/282173/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Rezolsta, darunavir,cobicistat, decision type: PM: decision on the ...

P/0257/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M06) Reference Number: EMA/306614/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Human medicines European public assessment report (EPAR): Cayston, aztreonam, Date of authorisation: 21/09/2009, Revision: 21, ...

In cystic fibrosis, the patient’s lungs produce too much thick mucus, which allows bacteria to grow more easily. In patients with cystic fibrosis, P. aeruginosa infections usually start in the first 10 years of life and can cause long-term lung problems …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Natpar, Recombinant parathyroid hormone, decision type: PM: decision on ...

P/0276/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M06) Reference Number: EMA/282640/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-001624-PIP01-14-M06

P/0277/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M06) Reference Number: EMA/282809/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-001821-PIP01-15-M07

P/0259/2023 : EMA decision of 13 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA- 001821-PIP01-15-M07) Reference Number: EMA/308500/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Xospata, Gilteritinib (as fumarate), decision type: PM: decision on the ...

P/0267/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate), (Xospata), (EMEA-002064-PIP01-16-M05) Reference Number: EMA/250923/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Camzyos, Mavacamten, decision type: PM: decision on the application for ...

P/0278/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mavacamten (EMEA- 002231-PIP01-17-M01) Reference Number: EMA/283075/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide ...

P/0246/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) (Apexxnar), (EMEA-002330-PIP01-18-M03) Reference Number: EMA/ …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Ayvakyt, Avapritinib, decision type: PM: decision on the application ...

P/0281/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for avapritinib (Ayvakyt), (EMEA-002358-PIP02-18-M03) Reference Number: EMA/315615/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application ...

P/0285/2023 : EMA decision of 24 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M01) Reference Number: EMA/333490/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-002472-PIP03-22-M01

P/0249/2023 : EMA decision of 5 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03-22-M01) Reference Number: EMA/289384/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-002572-PIP02-19-M03

P/0251/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for soticlestat (EMEA-002572-PIP02-19-M03) Reference Number: EMA/302913/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: PM: decision on the ...

P/0252/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP04-21-M01) Reference Number: EMA/303410/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-002631-PIP01-19-M02

P/0253/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed PIP for (4S,7aR,9aR,10S,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,7H-spiro[1,19-ethenocyclobuta[i][ …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

EMEA-002819-PIP01-20-M01

P/0263/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for magrolimab (EMEA- 002819-PIP01-20-M01) Reference Number: EMA/285601/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on July 12, 2024 - 14:40 GMT

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Toyota

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Toyota To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Toyota between June 25, 2022 and June 2, 2024 and would like to …

Distribution channels: Consumer Goods, Law ...

Published on July 12, 2024 - 14:39 GMT

EMEA-002886-PIP01-20-M03

P/0264/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for rocatinlimab (EMEA- 002886-PIP01-20-M03) Reference Number: EMA/285643/2023

Distribution channels: Healthcare & Pharmaceuticals Industry